Gyre Therapeutics Inc
GYRE
NASDAQ
Biotechnology
$6.68
USD
+0.14 (+2.14%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $736.94M
Volume 52.7K
Revenue
$119.38M
TTM
+13.5%
YoY
Gross Margin
94%
TTM
-1.8%
YoY
Net Income
$-28.28M
TTM
-561.5%
YoY
Operating Cash Flow
$-14.50M
TTM
-67.9%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 29.7 | 30.6 | 37.2 | 22.5 | 29.1 |
YoY Growth | +17.9% | +19.9% | +33.4% | +2.1% | -2.1% |
Cost of Revenue | 1.2 | 1.6 | 1.7 | 1.2 | 2.2 |
Gross Profit | 28.6 | 28.9 | 35.5 | 21.3 | 26.9 |
Selling, General & Administrative | 22.5 | 19.6 | 30.5 | 21.4 | 21.6 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 2.6 | 0.5 |
Total Operating Expenses | 30.8 | 22.0 | 35.3 | 30.6 | 41.3 |
Operating Income | -2.2 | 6.9 | 0.1 | -9.4 | -14.4 |
EBITDA | -1.2 | 7.6 | 0.8 | -8.7 | -12.9 |
Other Income / Expense | -0.3 | 0.7 | -1.9 | 0.1 | -0.8 |
Total Other Income / Expense | 0.7 | 0.7 | -0.2 | 0.1 | -0.1 |
Income Before Income Taxes | -1.6 | 7.6 | -0.1 | -9.2 | -14.4 |
Income Taxes | 0.7 | 1.7 | 1.3 | 0.6 | -0.2 |
Net Income | -1.0 | 5.9 | -1.4 | -9.9 | -23.0 |
Consolidated Net Income / Loss | -2.2 | 5.9 | -1.4 | -9.9 | -14.3 |
Net Income Attributable to Common Shareholders | -2.0 | 3.6 | -1.7 | -8.7 | -11.7 |
Basic EPS | -$0.02 | $0.04 | -$0.02 | -$0.10 | -$0.12 |
Diluted EPS | -$0.03 | $0.03 | -$0.01 | -$0.10 | -$0.12 |
Basic Shares Outstanding | 89.1M | 90.9M | 91.0M | 91.3M | 100.6M |
Diluted Shares Outstanding | 89.2M | 104.0M | 117.6M | 91.3M | 100.6M |